Estimating the stoichiometry of human immunodeficiency virus entry
about
Few and far between: how HIV may be evading antibody avidityCrystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regionsCell entry of enveloped virusesThe molecular basis of HIV entryDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityMathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entryEstimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusionVirus neutralisation: new insights from kinetic neutralisation curvesMorphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus EnvelopeFunctional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)Visualization of the two-step fusion process of the retrovirus avian sarcoma/leukosis virus by cryo-electron tomography.Analysis of the subunit stoichiometries in viral entry.Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.Estimating the stoichiometry of HIV neutralization.Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Negative potentials across biological membranes promote fusion by class II and class III viral proteinsHIV entry and envelope glycoprotein-mediated fusionFolded monomers and hexamers of the ectodomain of the HIV gp41 membrane fusion protein: potential roles in fusion and synergy between the fusion peptide, hairpin, and membrane-proximal external regionAdaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entryConditional trimerization and lytic activity of HIV-1 gp41 variants containing the membrane-associated segments.Binding of more than one Tva800 molecule is required for ASLV-A entry.High sensitivity detection and sorting of infectious human immunodeficiency virus (HIV-1) particles by flow virometry.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Full-length trimeric influenza virus hemagglutinin II membrane fusion protein and shorter constructs lacking the fusion peptide or transmembrane domain: Hyperthermostability of the full-length protein and the soluble ectodomain and fusion peptide maMolecular determinants of the ratio of inert to infectious virus particles.Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studiesRole of glycosphingolipids in dendritic cell-mediated HIV-1 trans-infection.Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping VirometryComplementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer.Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm.The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent.Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.Computer-Aided Approaches for Targeting HIVgp41.Multiscale modeling of virus replication and spread.How sticky should a virus be? The impact of virus binding and release on transmission fitness using influenza as an example.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsTwo distinct mechanisms regulate recruitment of murine leukemia virus envelope protein to retroviral assembly sites.Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
P2860
Q21090507-2CD57BF0-4007-4D52-92EB-BF194DB73BD8Q21090508-160E50B0-59F6-4088-ADB0-B9DC223C33DAQ26863682-B1F91EA8-F869-48A0-A990-4F38DE813638Q26863686-3570148D-0CFD-435D-8837-32F14DF408D6Q27654848-80799F10-9466-4D7A-ACE0-2A699FF9D40BQ28478310-B957943F-6E4C-40FA-B189-1003A5D319BAQ28478341-2ABCB5BC-6B7E-4B4C-AA8C-5372AEE99CE6Q28487427-E89D0F33-816D-4F19-B88F-3E04E4F3F070Q28550514-A63B70D7-C111-4FD7-9DDD-AA9521749F55Q28743199-77FDF3B1-1E32-4BD1-9BB5-75E2C2030415Q30419638-C6E8CBFF-19DF-46D8-A85D-3FF2FA8766E2Q31053897-70A41169-EE5C-4F7C-BC16-6016B4203C33Q31151010-CF4F2285-A4F9-47E8-87BE-73AA33FB45A1Q33545224-08E7AE6E-D16D-44BA-BBEB-2A01320174ADQ33638320-E4A886EF-E4D7-4502-90CE-404CA6AD1774Q33907054-5584D548-675A-4CB3-98DC-D6612EC782E2Q34435855-4ECB4442-7235-4D8D-91A0-05643575EAF3Q34579843-34CCD99A-A342-45BF-81ED-DF3968BB119AQ34610959-F02220F2-A523-4C32-BB6A-B6A2AFDE1E4DQ34875765-A116FEA6-4A6C-4398-80D4-47C5CCE38FB3Q35142768-EA4C0FEE-6379-4978-B7C4-D42E64CA1142Q35705083-F609138B-6944-43A6-8EB9-4C542356395EQ36290494-E6D22A76-97F8-4A1C-BE88-05578B5C65B4Q36298503-6A6B902A-1F79-45D0-A9E6-F97590CAEDDBQ36385125-B6FD2102-D403-4F1F-9868-6882518D3AB8Q36494676-112812AE-AE06-4362-89EB-6C26DFFA82A2Q36760147-C438395A-AFF1-4D8B-95FB-EE54FB5B0B7EQ36940332-59B33D77-C478-48EE-A142-3FF4CC6F8B87Q37065878-C9B8113A-8D75-41ED-98AB-9A843D7EAFBBQ37334851-8EB317A4-E6ED-435C-B0C0-680939AFE445Q37348882-60BE3D16-CBA1-4DFE-AFBB-4A8A716D843BQ37451938-495D69E0-A12E-4A50-A20E-744978753943Q37834097-F62EF3CB-2FA2-4E0E-9360-BD1CBE3F1811Q38050485-8DAA5B72-E8C5-421D-928A-58BA6F8CB941Q38111393-97FB0015-7DF6-4BB5-8506-5AAA656E3B30Q38733905-88BCD6DF-807E-4648-9AD9-A012F70F2F74Q39271411-8E1FE710-5F20-49FA-93EC-FF0366FCE7F6Q39454698-CFDF4B66-3B9D-4140-B25E-FCCA6FAFA3ADQ39676464-628BCA53-2CD6-4867-8832-28C16521BEA5Q39870010-AD5398CB-ACA6-4664-B18D-38EEFA6F822A
P2860
Estimating the stoichiometry of human immunodeficiency virus entry
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Estimating the stoichiometry of human immunodeficiency virus entry
@en
Estimating the stoichiometry of human immunodeficiency virus entry.
@nl
type
label
Estimating the stoichiometry of human immunodeficiency virus entry
@en
Estimating the stoichiometry of human immunodeficiency virus entry.
@nl
prefLabel
Estimating the stoichiometry of human immunodeficiency virus entry
@en
Estimating the stoichiometry of human immunodeficiency virus entry.
@nl
P2860
P50
P356
P1433
P1476
Estimating the stoichiometry of human immunodeficiency virus entry
@en
P2093
Peter Rusert
Roland R Regoes
P2860
P304
P356
10.1128/JVI.01764-08
P407
P577
2008-11-19T00:00:00Z